Lawmakers Push Back on Prediction Markets Tied to Drug Approvals
Two senators are questioning HHS about risks posed by prediction markets linked to clinical trials and pharmaceutical approvals.
Prediction markets have been around for a while, but a new frontier is raising serious red flags on Capitol Hill: markets that let people essentially bet on whether a drug will get approved or a clinical trial will succeed. Senators Angela Alsobrooks and Ron Wyden are now pressing the Department of Health and Human Services to explain what, if anything, it's doing to keep those markets in check.
The concern here isn't hard to understand. When real money rides on the outcome of a drug approval, the incentives around that process can get murky fast. Critics worry that participants with insider knowledge — or worse, the ability to influence outcomes — could game these markets in ways that undermine the integrity of the entire clinical trial system. That's a pretty big deal when we're talking about medications that millions of people might eventually take.
Read more Germany Eyes Crypto Seizures Even Without Criminal Charges →
Alsobrooks and Wyden are specifically asking HHS what steps the agency has already taken to mitigate the risks these markets create. It's a pointed question, and the fact that two lawmakers felt compelled to put it in writing suggests they're not entirely satisfied with the status quo. The letter signals that congressional oversight of prediction markets is expanding well beyond the financial and political arenas where these platforms first gained mainstream attention.
Prediction markets work by aggregating crowd wisdom — or crowd speculation — into probability estimates for future events. In theory, they can be useful forecasting tools. But when the events being predicted involve regulated medical processes and public health, the stakes are fundamentally different than, say, forecasting an election outcome. The pharmaceutical approval pipeline is already a high-pressure environment; layering financial speculation on top of it adds a whole new set of variables that regulators may not be equipped to handle yet.
Whether HHS responds with new guidance, defers to other agencies, or acknowledges gaps in oversight remains to be seen. But the senators' letter puts the issue squarely on the federal agenda. Continue reading at US Top News and Analysis.